Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

bit.bio partners with Automata to automate a key aspect of its production of iPSC derived human cells

...

From Automata 26 Jan 2023

Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neurodegenerative, renal, and cardiovascular diseases.

From Ubiquigent Limited 23 Jan 2023

Optibrium appoints Steve Yemm as Chief Commercial Officer

New role will lead global commercial strategy and development as Optibrium continues to scale its drug discovery technologies and team.

From Optibrium Ltd. 17 Jan 2023

Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs

...

From Orbit Discovery 5 Jan 2023

New technologies reveal cross-cutting breakdowns in Alzheimer’s disease

A figure from the paper depicts pathways perturbed in Alzheimer's disease. Below examples are listed for each pathway by major brain cell type. Image Credit: The Picower Institute.

4 Jan 2023

Molecular motion of “undruggable” proteins reveals drug-binding sites

“Undruggable” proteins, whose structures and roles in disease are known but who appear unable to be targeted by drugs that will bind to them, present some of the hardest problems in disease treatment.

23 Nov 2022

Optibrium appoints Ian Smith as Chief Technology Officer

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the appointment of Ian Smith as Chief Technology Officer (CTO), the latest in a number of senior-level hires for the Company.

From Optibrium Ltd. 23 Nov 2022

Providing structural understanding of the influenza virus

The structure of the influenza replication machinery and how it interacts with cellular proteins have been solved by a team of Oxford University scientists using a variety of techniques at Diamond Light Source.

8 Nov 2022

New bioprinting platform to replicate tumors in 3D spheroids

Bowel cancer patients could in future benefit from a new 3D bioprinting technology which would use their own cells to replicate the complex cellular environment of solid tumors in 3D models.

3 Nov 2022

Drug discovery method facilitates promising treatment approaches for metabolic diseases

The body’s chemical processes known as “metabolism” produce the raw materials needed for development and general health.

17 Oct 2022

PhoreMost enters multi-project drug target discovery collaboration with Roche

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes

From PhoreMost 6 Sep 2022

Detecting multiple food poisoning bacteria based on color differences in scattered light from metals

Osaka Metropolitan University scientists have developed a simple, rapid method to simultaneously identify multiple food poisoning bacteria, based on color differences in the scattered light by nanometer-scaled organic metal nanohybrid structures (NHs) that bind via antibodies to those bacteria.

30 Aug 2022

Inventia Life Science Accelerates Growth with AU$35 million Series B Led by Blackbird Ventures, Launching 3D Cell Culture Platform into US Market

Company aims to democratise access to affordable biomedical research especially in cancer research and new drug development through its novel 3D cell culture platform